ClinicalTrials.gg
Active, not recruitingNCT03981796RUBYUpdated Sep 3, 2025

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

A Phase 3 interventional study of Dostarlimab and Placebo matching dostarlimab in Neoplasms, sponsored by Tesaro, Inc.. Active, not recruiting at 169 sites in 20 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
785
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.

02

Conditions studied

  • Neoplasms

Keywords

  • Dostarlimab
  • Carboplatin
  • Paclitaxel
  • Niraparib
  • Recurrent or primary advanced endometrial cancer
  • TSR-042
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 785 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

First submitted after Tesaro, Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1 and Part 2:

  • Female participant is at least 18 years of age.
  • Participant has or cytologically proven endometrial cancer with recurrent or advanced disease.
  • Participant must have primary Stage III or Stage IV disease or first recurrent endometrial cancer with a low potential for cure by radiation therapy or surgery alone or in combination and meet at least one of the following criteria;

    1. Participant has primary Stage IIIA to IIIC1 disease with presence of evaluable or per (RECIST) version (v).1.1 based on Investigator's assessment. Lesions that are equivocal or can be representative of post-operative change should be biopsied and confirmed for the presence of tumor;
    2. Participant has primary Stage IIIC1 disease with carcinosarcoma, clear cell, serous, or mixed histology (containing greater than or equal to [>=] 10 percent carcinosarcoma, clear cell, or serous histology) regardless of presence of evaluable or measurable disease on imaging;
    3. Participant has primary Stage IIIC2 or Stage IV disease regardless of the presence of evaluable or measurable disease;
    4. Participant has first recurrent disease and is naïve to systemic anticancer therapy;
    5. Participant has received prior /adjuvant systemic anticancer therapy and had a recurrence or progression of disease (PD) >=6 months after completing treatment (first recurrence only).
  • Participant has an performance status of 0 or 1.
  • Participant has adequate organ function.

Part 2 only:

  • Participants must have normal blood pressure (BP) or adequately treated and controlled hypertension (systolic BP lesser than or equal to [\<=] 140 millimeter of mercury [mmHg] and diastolic BP \<=90 mmHg).
  • Participants must be able to take medication orally, by mouth (PO).

Exclusion criteria

Exclusion Criteria:

Part 1 and Part 2:

  • Participant has received /adjuvant systemic anticancer therapy for primary Stage III or IV disease and:

    1. has not had a recurrence or PD prior to first dose on the study OR
    2. has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
  • Participant has had >1 recurrence of endometrial cancer.
  • Participant has received prior therapy with an anti-programmed cell death protein 1 (), anti-PD-ligand 1 (anti-PD-L1), or anti-PD-ligand 2 (anti-PD-L2) agent.
  • Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days or \<5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.
  • Participant has a concomitant , or participant has a prior non-endometrial invasive malignancy who has been disease-free for \<3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
  • Participant has known uncontrolled central nervous system , carcinomatosis meningitis, or both.
  • Participant has not recovered (that is [i.e.], to Grade \<=1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
  • Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
  • Participant is currently participating and receiving study treatment or has participated in a study of an agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
  • Participant has received, or is scheduled to receive, a within 30 days before first dose of study treatment, during study treatment, and for up to 180 days after receiving the last dose of study treatment.

Part 2 only:

  • Participant has received prior therapy with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor.
  • Participant has cardiovascular disease.
  • Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • Participant is at increased bleeding risk due to concurrent conditions.
  • Participant has participated in Part 1 of this study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
785 participants (actual)

Study arms

  • Active comparator
    Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab

    Biological: Dostarlimab · Drug: Carboplatin · Drug: Paclitaxel

  • Placebo comparator
    Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

    Drug: Placebo matching dostarlimab · Drug: Carboplatin · Drug: Paclitaxel

  • Active comparator
    Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib

    Biological: Dostarlimab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Niraparib

  • Placebo comparator
    Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

    Drug: Placebo matching dostarlimab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Placebo matching Niraparib

Interventions

  • BiologicalDostarlimab

    Participants will be administered dostarlimab

    Also known as: TSR-042

  • DrugPlacebo matching dostarlimab

    Participants will be administered placebo matching dostarlimab

  • Participants will be administered carboplatin

  • Participants will be administered paclitaxel

  • Participants will be administered niraparib

  • DrugPlacebo matching Niraparib

    Participants will be administered placebo matching Niraparib

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessment

    Time frame: Up to 6 years

  2. Part 1: Overall survival

    Time frame: Up to 6 years

Secondary outcomes

  1. Part 2: Overall survival

    Time frame: Up to 6 years

  2. Parts 1 and 2: Progression free survival (PFS) blinded independent central review (BICR)

    Time frame: Up to 6 years

  3. Parts 1 and 2: Objective response rate (ORR) - BICR and Investigator assessment

    Time frame: Up to 6 years

  4. Parts 1 and 2: Duration of response (DOR) - BICR and Investigator assessment

    Time frame: Up to 6 years

  5. Parts 1 and 2: Disease control rate (DCR) - BICR and Investigator assessment

    Time frame: Up to 6 years

  6. Parts 1 and 2: Patient-reported outcomes (PROs) in the European Quality of Life scale, 5-Dimensions, 5-Levels (EQ-5D-5L)

    EQ-5D-5L is a validated questionnaire to assess the overall health-related quality of life in participants across diseases.

    Time frame: Up to 6 years

  7. Parts 1 and 2: PROs in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30 [Core])

    EORTC QLQ-C30 is validated questionnaire to assess overall health-related quality of life in participants with cancer.

    Time frame: Up to 6 years

  8. Parts 1 and 2: PROs in the EORTC Quality of Life Questionnaire (Endometrial Cancer Module [QLQ-EN24])

    EORTC QLQ-EN24 is a validated questionnaire to assess the overall health-related quality of life in participants with all stages of endometrial cancer.

    Time frame: Up to 6 years

  9. Parts 1 and 2: Progression-free survival 2 (PFS2)

    Time frame: Up to 6 years

  10. Parts 1 and 2: Number of participants with adverse events (AEs), Serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)

    Time frame: Up to 6 years

  11. Parts 1 and 2: Number of participants with clinically significant changes in clinical laboratory parameters, physical examination, electrocardiogram (ECG) and participants reporting the intake of concomitant medication

    Time frame: Up to 6 years

  12. Parts 1 and 2: Change from Baseline in vital sign: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (Millimeters of mercury)

    Time frame: Baseline and up to 6 Years

  13. Parts 1 and 2: Change from Baseline in vital sign: Heart Rate

    Time frame: Baseline and up to 6 Years

  14. Parts 1 and 2: Change from Baseline in vital sign: Respiratory rate

    Time frame: Baseline and up to 6 Years

  15. Parts 1 and 2: Change from Baseline in vital sign: Body temperature

    Time frame: Baseline and up to 6 Years

  16. Parts 1 and 2: Number of participants with Eastern Cooperative Oncology Group (ECOG) Performance Status Scores

    Performance status will be assessed using the ECOG scale, with status score ranging from 0 to 5.

    Time frame: Up to 6 years

  17. Parts 1 and 2: Minimum observed concentration (Cmin) and maximum observed concentration (Cmax) of dostarlimab (micrograms per milliliter)

    Time frame: Predose (Day 1) and postdose (Day 1) of Cycles 1, 2, 6, 7, 10, 15, and 20 (Cycle 1, 2, 6 is 21 days and Cycle 7, 10, 15, 20 is 42 days)

  18. Parts 1 and 2: Cmin and Cmax at steady state of dostarlimab (micrograms per milliliter)

    Time frame: Predose (Day 1) and postdose (Day 1) of Cycles 1, 2, 6, 7, 10, 15, and 20 (Cycle 1, 2, 6 is 21 days and Cycle 7, 10, 15, 20 is 42 days)

  19. Part 2: Cmin and Cmax of niraparib (nanograms per milliliter)

    Time frame: Predose (Day 1) and 3 hours postdose (Day 1) of Cycles 7 and 8 and Predose (Day 1) of Cycles 10 and 14 (each cycle is 42 days)

  20. Part 2: Cmin and Cmax at steady state of niraparib (nanograms per milliliter)

    Time frame: Predose (Day 1) and 3 hours postdose (Day 1) of Cycles 7 and 8 and Predose (Day 1) of Cycles 10 and 14 (each cycle is 42 days)

  21. Parts 1 and 2: Number of participants with anti-drug antibodies (ADA) against dostarlimab

    Time frame: Predose (Day 1)

07

Study locations

169 sites
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85016, United States
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Tucson, Arizona 85710, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Palo Alto, California 94304, United States
  • GSK Investigational Site
    Deerfield Beach, Florida 33442, United States
  • GSK Investigational Site
    Jacksonville, Florida 32207, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Hinsdale, Illinois 60521, United States
  • GSK Investigational Site
    Zion, Illinois 60099, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46845, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46260, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01199, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    St Louis, Missouri 63108, United States
  • GSK Investigational Site
    Lebanon, New Hampshire 03756, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87131, United States
  • GSK Investigational Site
    Rio Rancho, New Mexico 87124, United States
  • GSK Investigational Site
    Albany, New York 12208, United States
  • GSK Investigational Site
    Mineola, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Kernersville, North Carolina 27284, United States
  • GSK Investigational Site
    Mount Airy, North Carolina 27030, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45219, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45220, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Hilliard, Ohio 43026, United States
  • GSK Investigational Site
    Hilliard, Ohio 43210, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74146, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • GSK Investigational Site
    Willow Grove, Pennsylvania 19090, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37920, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Austin, Texas 78758, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Dallas, Texas 76104, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22903, United States
  • GSK Investigational Site
    Roanoke, Virginia 24016, United States
  • GSK Investigational Site
    Seattle, Washington 98109, United States
  • GSK Investigational Site
    Grodno, 230030, Belarus
  • GSK Investigational Site
    Minsk, 223040, Belarus
  • GSK Investigational Site
    Aalst, 9300, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Calgary, Alberta T2N 5G2, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Sault Ste. Marie, Ontario P6B 0A8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3E4, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Québec, Quebec G1J 1Z4, Canada
  • GSK Investigational Site
    Brno, 625 00, Czechia
  • GSK Investigational Site
    Prague, 128 51, Czechia
  • GSK Investigational Site
    Aalborg, 9000, Denmark
  • GSK Investigational Site
    Copenhagen, DK-2100, Denmark
  • GSK Investigational Site
    Herlev, 2730, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Roskilde, 4000, Denmark
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Tampere, 33520, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Amberg, 92224, Germany
  • GSK Investigational Site
    Bad Homburg, 61352, Germany
  • GSK Investigational Site
    Cologne, 50935, Germany
  • GSK Investigational Site
    Dessau, 06847, Germany
  • GSK Investigational Site
    Dresden, 01307, Germany
  • GSK Investigational Site
    Essen, 45136, Germany
  • GSK Investigational Site
    Essen, 45147, Germany
  • GSK Investigational Site
    Frankfurt, 20259, Germany
  • GSK Investigational Site
    Giessen, 35392, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Hanover, 30177, Germany
  • GSK Investigational Site
    Jena, 07747, Germany
  • GSK Investigational Site
    Karlsruhe, 76135, Germany
  • GSK Investigational Site
    Kiel, 24105, Germany
  • GSK Investigational Site
    Lübeck, 23538, Germany
  • GSK Investigational Site
    Mainz, 55131, Germany
  • GSK Investigational Site
    München, 81675, Germany
  • GSK Investigational Site
    Offenbach, 63069, Germany

Showing the first 100 of 169 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novak Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. PubMed 36972026 ↗
  • Chen Y, Lubinga SJ, Ramsey S, Hurteau J, Reynolds J, Carlson JJ. Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis. JCO Precis Oncol. 2026 Jul;10(7):e2501110. doi: 10.1200/PO-25-01110. Epub 2026 Jul 6. PubMed 42407008 ↗
  • Chase DM, Herrstedt J, Miller EM, Gilbert L, Zub O, Mathews C, Angioli R, Teneriello M, Gropp-Meier M, Powell MA, Reyners AKL, Cloven NG, Eminowicz G, Gill SE, Mackowiak-Matejczyk B, Pothuri B, Samouelian V, Jain A, Boone J, Bouberhan S, Trinidad J, Braly P, Buttin B, Backes FJ, Sawyer B, Antony G, Garside J, Allonby O, McCourt CK, Mirza MR. Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel. Int J Gynecol Cancer. 2025 Aug;35(8):101935. doi: 10.1016/j.ijgc.2025.101935. Epub 2025 May 21. PubMed 40616865 ↗
  • Banerjee S, Ingles Russo Garces A, Garside J, Rahman T, Pearson C, Heffernan K. Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study. BMJ Open. 2024 Nov 24;14(11):e083540. doi: 10.1136/bmjopen-2023-083540. PubMed 39581729 ↗
  • Auranen A, Powell MA, Sukhin V, Landrum LM, Ronzino G, Buscema J, Bauerschlag D, Lalisang R, Bender D, Gilbert L, Armstrong A, Safra T, Nevadunsky N, Sebastianelli A, Slomovitz B, Ring K, Coleman R, Podzielinski I, Stuckey A, Teneriello M, Gill S, Pothuri B, Willmott L, Sharma S, Dabrowski C, Antony G, Stevens S, Mirza MR, Fleming E. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Ther Adv Med Oncol. 2024 Sep 28;16:17588359241277656. doi: 10.1177/17588359241277656. eCollection 2024. PubMed 39346117 ↗
  • Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, Denschlag D, Myers T, Thijs AM, Pennington KP, Gilbert L, Fleming E, Zub O, Landrum LM, Ataseven B, Gogoi R, Podzielinski I, Cloven N, Monk BJ, Sharma S, Herzog TJ, Stuckey A, Pothuri B, Secord AA, Chase D, Vincent V, Meyers O, Garside J, Mirza MR, Black D. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial. Int J Gynecol Cancer. 2025 Jun;35(6):101852. doi: 10.1136/ijgc-2024-005484. Epub 2025 Apr 19. PubMed 39322611 ↗
  • Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novak Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". Future Oncol. 2025 Jan;21(2):151-168. doi: 10.2217/fon-2023-0940. Epub 2024 Jul 11. PubMed 38990090 ↗
  • Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May;35(5):414-428. doi: 10.1016/j.annonc.2024.02.006. Epub 2024 Feb 29. PubMed 38431043 ↗
  • You M, Zeng X, Zhang J, Huang Y, Zhang Y, Cai Z, Hu Y. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer. Front Immunol. 2023 Sep 4;14:1267322. doi: 10.3389/fimmu.2023.1267322. eCollection 2023. PubMed 37731489 ↗
  • Morton M, Marcu I, Levine M, Cosgrove C, Backes F, O'Malley D, Chambers L. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma. Obstet Gynecol. 2023 Aug 1;142(2):360-363. doi: 10.1097/AOG.0000000000005243. Epub 2023 Jul 5. PubMed 37411031 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Nov 2026, 88 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 88 months is above that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2019
First posted
Jun 11, 2019
StartActual
Jul 18, 2019
Primary completionEst.
Nov 26, 2026
CompletionEst.
Nov 26, 2026
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03981796
Lead sponsor
Tesaro, Inc.
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Responsible party
Sponsor
First posted
Jun 11, 2019
Start date
Jul 18, 2019
Primary completion
Nov 26, 2026 (estimated)
Completion
Nov 26, 2026 (estimated)
Last update
Sep 3, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Niraparib

Start the discussion